InMed Pharmaceuticals Inc

INM03 Dec 2024
Healthcare
$4.3
+0.01 (+0.93%)
Lowest Today
$4.22
Highest Today
$4.45
Today’s Open
$4.3
Prev. Close
$4.29
52 Week High
$9.44
52 Week Low
$2.42
To Invest in InMed Pharmaceuticals Inc

InMed Pharmaceuticals Inc

Healthcare
INM03 Dec 2024
+0.01 (+0.93%)
1M
3M
6M
1Y
5Y
Low
$4.22
Day’s Range
High
$4.45
4.22
52 Week Low
$2.42
52-Week Range
52 Week High
$9.44
2.42
1 Day
-
1 Week
-2.05%
1 month return
+1710.12%
3 month return
+1232.29%
6 month return
+1305.63%
1 Year return
+916.58%
3 Years return
-88.24%
5 Years return
-
10 Years return
-
Institutional Holdings
AdvisorShares Pure Cannabis ETF
5.8
AdvisorShares Investments, LLC
5.11
Sabby Management LLC
2.14
Virtu Financial LLC
0.6
Renaissance Technologies Corp
0.35
HRT FINANCIAL LLC
0.27
Baader Bank INC
0.16
Fundamentals
Market Cap
3.09 mln
PB Ratio
0.37
PE Ratio
0.02
Enterprise Value
-1.44 mln
Total Assets
11.82 mln
Volume

Company Financials

Fund house & investment objective

Company Information
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Organisation
InMed Pharmaceuticals Inc
Employees
13
Industry
Biotechnology
CEO
Mr. Eric A. Adams B.S. Chem., M.I.B.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities